Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.31 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15252802 | 0.83 | GABRR1 (0.32) | DPP4DPP8 | |
| SCHEMBL12192557 | 0.83 | ATM (0.35) | ATMMMP2ANPEPCHRNB2CHRNA3 | |
| SCHEMBL12192550 | 0.83 | ATM (0.35) | ATMMMP2ANPEPCHRNB2CHRNA3 | |
| SCHEMBL20956816 | 0.83 | GABRR1 (0.32) | DPP4DPP8 | |
| SCHEMBL12192539 | 0.80 | ATM (0.33) | ATMMMP2ANPEPDPP4DPP8 | |
| SCHEMBL12192533 | 0.80 | ATM (0.33) | ATMMMP2ANPEPDPP4DPP8 | |
| SCHEMBL12192543 | 0.79 | MMP2 (0.33) | ATMMMP2ANPEP | |
| SCHEMBL12192545 | 0.79 | MMP2 (0.36) | ATMMMP2ANPEP | |
| SCHEMBL12192563 | 0.79 | MMP2 (0.36) | ATMMMP2ANPEP | |
| SCHEMBL3415474 | 0.77 | NR1H2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030495-B2 | Cyclopropyl pyrrolidine orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2011-10-04 | — | — | US | disclosed |
| US-20100152191-A1 | CYCLOPROPYL PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152191-A1 | CYCLOPROPYL PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, OXTR | ATM 4835/4885MMP2 3423/4885ANPEP 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.